RUNX1 and neoplasm: Notably, AML1–ETO, as a dominant negative oncoprotein, repressed the ARF promoter and reduced endogenous levels of ARF expression, indicating that RUNX1 functions upstream of the tumor suppressive ARF–p53 pathway [60].